Older adults may have a second vaccine option for RSV following the U.S. Food and Drug Administration’s approval of a Pfizer vaccine on Wednesday.
The other shot for adults 60 and up is made by GSK. It was approved May 3.
Both should be available by fall, before the seasonal spread of respiratory syncytial virus (RSV), The New York Times reported.
The Pfizer vaccine, known as Abrysvo, has effectiveness of nearly 67% when a patient has two symptoms of RSV, such as a sore throat and cough. It’s 86% effective when three or more symptoms surface.
